GlassScriptPhysician profile
Nadia Yusuf
NPI 1497192272
$16,777.67
in general payments reported to CMS, 2019-2025
61 companies · $2,949 in 2025
The $2,949 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $2,554 · 2021: $1,270 · 2022: $2,793 · 2023: $2,269 · 2024: $3,062 · 2025: $2,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,697 · Education: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,696.62 |
| Education | $582.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,324.56 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $2,173.90 | 2021-2025 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $2,147.39 | 2019-2025 | |
| Pfizer INC. | $809.98 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $792.27 | 2019-2025 | Nuplazid, Daybue |
| Mdd US Operations, LLC | $633.58 | 2019-2025 | Gocovri, Gocovri |
| Sunovion Pharmaceuticals INC. | $579.80 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $522.82 | 2020-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $471.78 | 2019-2022 | |
| Lilly USA, LLC | $441.48 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Emd Serono, INC. | $387.14 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $357.91 | 2019-2025 | Vyepti |
| Biogen, INC. | $353.30 | 2020-2025 | Vumerity, Spinraza, Tysabri |
| Biohaven Pharmaceutical Holding Company LTD. | $307.67 | 2022 | |
| Medtronic USA, INC. | $271.49 | 2019 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $257.64 | 2019-2024 | Nayzilam, Briviact |
| Alexion Pharmaceuticals, INC. | $256.93 | 2020-2024 | Soliris |
| Adamas Pharmaceuticals, INC. | $239.71 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $227.88 | 2019-2025 | Rytary, Ongentys 50mg Capsules 30, Ongentys |
| Amgen INC. | $221.19 | 2019-2023 | Aimovig |
| Eisai INC. | $195.82 | 2022-2025 | |
| Genzyme Corporation | $195.17 | 2019-2025 | |
| Kyowa Kirin, INC. | $176.46 | 2020-2023 | Nourianz |
| Livanova USA, INC. | $150.41 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $147.71 | 2023-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $142.71 | 2022-2025 | Qelbree |
| Boston Scientific Corporation | $142.14 | 2019-2024 | Bodyguardian |
| Biohaven Pharmaceuticals, INC. | $135.09 | 2021 | |
| Upsher-Smith Laboratories LLC | $133.19 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $130.63 | 2019-2025 | Dysport |
| Ge Healthcare | $124.06 | 2021-2025 | |
| Banner Life Sciences, LLC | $108.77 | 2022-2024 | |
| Merz Pharmaceuticals, LLC | $105.26 | 2021-2025 | Xeomin |
| Merz North America, INC. | $82.55 | 2019 | |
| Ani Pharmaceuticals, INC. | $80.71 | 2024-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $76.63 | 2019-2023 | Infinity |
| Axsome Therapeutics, INC. | $76.28 | 2024-2025 | Sunosi |
| Avion Pharmaceuticals | $70.93 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $68.11 | 2025 | Lumryz |
| Genentech USA, INC. | $63.17 | 2019-2021 | |
| Celgene Corporation | $58.54 | 2021-2025 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $50.31 | 2020-2023 | Firdapse |
| Acorda Therapeutics, INC | $48.05 | 2019-2022 | |
| Averitas Pharma INC. | $44.13 | 2024 | Qutenza |
| Vertical Pharmaceuticals, LLC | $41.35 | 2019-2020 | |
| Revance Therapeutics, INC. | $40.85 | 2024-2025 | Daxxify |
| Csl Behring | $35.64 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $29.55 | 2024 | Aptiom |
| Impel Pharmaceuticals LLC | $24.46 | 2025 | Trudhesa |
| Harmony Biosciences LLC | $24.39 | 2025 | |
| Cardinal Health 414 LLC | $23.97 | 2025 | |
| Tanabe Pharma America, INC. | $22.64 | 2024 | |
| Octapharma USA, INC. | $20.46 | 2023 | Panzyga |
| Grifols USA, LLC | $20.39 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.13 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.12 | 2020 | |
| Argenx US, INC. | $15.99 | 2023 | Vyvgart |
| Tms Neurohealth Centers INC. | $15.70 | 2025 | Tms Neurohealth Centers INC. |
| Vanda Pharmaceuticals INC. | $15.51 | 2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $12.69 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Yusuf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.